Ventas, Inc. (VTR) is a leading healthcare REIT valued at $30.6 billion, with a diverse portfolio of 1,400 properties. Despite a 5.6% drop from its 52-week high, VTR stock has risen 7.5% in the past three months and 14.5% YTD, outperforming its industry peers.

Following Q2 2025 results, Ventas posted a normalized FFO of $0.87 per share, beating estimates with revenues of $1.42 billion. The company raised its 2025 normalized FFO guidance to $3.41-$3.46 per share and increased its senior housing investment outlook to $2.0 billion.

While Ventas has underperformed compared to Welltower Inc. (WELL), analysts remain bullish with a “Strong Buy” consensus rating. The mean price target of $77.39 represents a 14.9% premium to current levels. Ventas stock has been trading above its 200-day moving average since last year.

Read more at Yahoo Finance: How Is Ventas’ Stock Performance Compared to Other Real Estate Stocks?